BD, Labcorp Collaborate on Flow Cytometry-Based Diagnostics
Medical technology company BD (Becton, Dickinson and Company) announced a collaboratation agreement with life sciences company Labcorp to develop flow cytometry-based companion diagnostics intended to match patients with life-changing treatments for cancer and other diseases.
According to Labcorp Chief Scientific Officer Bill Hanlon, the collaboration is a step toward increasing the adoption of flow cytometry in oncology and other therapeutic areas and developing methods to help pair patients with appropriate treatments. Current companion diagnostic tests commonly use technologies such as immunohistochemistry, fluorescence in situ hybridization, polymerase chain reaction, next-generation sequencing, and imaging.
The agreement provides a framework for BD and Labcorp Drug Development to collaborate with pharmaceutical partners. The companies' joint offering ranges from exploratory panel development to U.S. Food and Drug Administration approval of diagnostic and in vitro diagnostics kit manufacturing and distribution.
LATEST NEWS
- Active Surfaces Secures $5.6M in Funding for Solar Tech: Week in Brief: 5/17/24
May 17, 2024
- Quantum State Opens Possibility for Advances in Optoelectronics
May 17, 2024
- LED Display Guides Surgery with Real-Time Visuals of Brain Activity
May 16, 2024
- George Mason University Receives Air Force Funding for Imaging, Digital Twins Lab
May 16, 2024
- Intel Appoints Vice President, General Manager of Foundry Arm: People in the News: 5/15/24
May 15, 2024
- Agreements Fortify NVIDIA's Role as Global Partner in Quantum Supercomputing
May 15, 2024
- Compact Single-Photon Lidar Provides High Resolution for Air and Space
May 14, 2024
- Lightium Receives $2.9M to Commercialize Data Center Tech
May 14, 2024